Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Novo Downplays Afrezza, Pins Hopes On Oral Pipeline

This article was originally published in PharmAsia News

Executive Summary

Novo Nordisk appears not to be worried about any market impact from Afrezza, MannKind’s recently approved inhalable insulin. In an exclusive interview in Copenhagen, the Danish company’s leadership told PharmAsia News that it had taken sufficient steps to maintain its stronghold on the global insulin market.

You may also be interested in...



MannKind Scores Sanofi As A Partner For Afrezza – But At A Price

Sanofi appears to be an ideal match to sell MannKind’s inhaled insulin Afrezza, but the terms of the exclusive worldwide licensing agreement for the product reflect its high-risk nature.

How Afrezza’s Labeling Stacks Up To NovoLog and Exubera

MannKind’s inhaled insulin resulted in a lesser degree of hemoglobin A1c reduction than Novo Nordisk’s insulin aspart in a pivotal study in type 1 diabetics.

Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk

FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel